Boehringer Ingelheim buys oncology biotech for up to $1.3B

Boehringer In­gel­heim is pay­ing up to $1.3 bil­lion to ac­quire a rel­a­tive­ly un­known im­muno-on­col­o­gy biotech out of La Jol­la, CA.

The Ger­man drug gi­ant …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.